Updated: J&J axes four-year discovery alliance with Morphic
J&J and Harvard spinout Morphic Therapeutic are parting ways after four years of working together on finding small molecule drugs that can act on new integrin targets.
Morphic quietly disclosed on Friday that it received a termination notice from J&J’s Janssen a week ago. AbbVie broke off a similar deal with Morphic back in June. In its filing, the biotech did not specify why Janssen walked away, noting only that the pharma partner exercised its right to end the R&D collaboration “for convenience.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.